ライフサイエンスコーパス: glycemic

1 profibrotic markers that were independent of glycemic and lipid changes.

2 er A) locus has been associated with several glycemic and metabolic traits in genome-wide association

3 ies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better

4 ELE exerts its effect on CAD through immune, glycemic, and lipid metabolism, making it a candidate of

5 (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits).

6 ated by mTORC1, including insulin signaling, glycemic balance, and adipocyte differentiation.

7 interventions had the strongest evidence for glycemic benefit among intervention types.

8 were not associated with differences in any glycemic biomarkers.

9 These results suggest that a high glycemic burden in patients with T1D is related to expre

10 rate of monocytes in patients with a higher glycemic burden.

11 gene expression profile associated with high glycemic burden.

12 High glycemic carbohydrate foods are linked to higher risk of

13 ported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-eff

14 Controlled glycemic concentrations are associated with a lower risk

15 Under different glycemic conditions, ZEB1 binding to E-cadherin promoter

16 en neighborhood supermarket gain or loss and glycemic control (assessed by glycated hemoglobin (HbA1c

17 basal insulin also correlated with efficient glycemic control (blood glucose <120 mg/dL), prevention

18 Intensive glycemic control (IGC) targeting HbA1c fails to show an

19 a-level attributes and according to baseline glycemic control (near normal, <6.5%; good, 6.5%-7.9%; m

20 sought to determine the relationship between glycemic control (random blood glucose [RBG], fasting bl

21 ignaling pathways contribute to the improved glycemic control achieved with adropin(34-76) treatment

22 Bile acids (BAs) are key mediators of the glycemic control after bariatric surgeries.

23 As glycemic control alone does not prevent complications, w

24 he Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults With

25 dults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes

26 as an add-on to insulin therapy resulted in glycemic control and a periodontal tissue response to or

27 The authors observed glycemic control and a reduction in body weight, intrahe

28 y during these years is associated with poor glycemic control and complications from diabetes in adul

29 Understanding the genetic basis of glycemic control and HbA(1c) may lead to better preventi

30 ralized testing of I and C towards a tighter glycemic control and improved management of diabetes.

31 inflammation of T2D and associates with poor glycemic control and increased T2D morbidity.

32 We sought to assess the effects of intensive glycemic control and intensive blood pressure control on

33 dy (N = 23,294), component GRSs discriminate glycemic control and lipid-based genetic risk, while rev

34 y, continuous glucose monitoring can improve glycemic control and neonatal outcomes in women with typ

35 ith newly diagnosed T1D, rs7804356 predicted glycemic control and residual beta-cell function during

36 proposed as a potential target for improving glycemic control and suppressing binge eating behaviors.

37 ected to have consequential bearings on IAPP glycemic control and T2D pathology.

38 g that different mechanisms explain improved glycemic control and weight loss after these surgical pr

39 se patterns change as a function of improved glycemic control are warranted.

40 se patterns change as a function of improved glycemic control are warranted.

41 Participants in the intensive glycemic control arm did not have an increased risk of Q

42 ncreased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely t

43 ms in men) in the intensive versus standard glycemic control arms.

44 iabetes, supporting a mechanism for improved glycemic control associated with maintenance of function

45 ries for those with good, moderate, and poor glycemic control at baseline, while supermarket gain was

46 The certainty of evidence for glycemic control by subgroup was moderate for multicompo

47 ed with standard glycemic control, intensive glycemic control caused increased mortality in the Actio

48 treatment strategies developed strictly for glycemic control did not confer a large risk reduction i

49 l and neonatal outcomes, and optimization of glycemic control during pregnancy can help mitigate risk

50 , increases energy expenditure, and improves glycemic control equally well in mice treated with antib

51 Intensive glycemic control has been a major focus for clinical tri

52 However, early loss of glycemic control has been observed with metformin monoth

53 Second, although glycemic control has been recommended as a part of compr

54 ammatory responses in the liver and improved glycemic control immediately after allogeneic PITx and s

55 ype 1 diabetes therapies that afford tighter glycemic control in a more manageable and painless manne

56 e monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents a

57 ffect of tree nuts and peanuts on markers of glycemic control in adults.

58 A treat-to-target approach led to good glycemic control in both groups, and there was no signif

59 K effectively regulates liver metabolism and glycemic control in diabetic mice in a LKB1-dependent ma

60 d standard procedure for assessing long term glycemic control in individuals with diabetes mellitus a

61 widely used to diagnose diabetes and assess glycemic control in individuals with diabetes.

62 ype 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available

63 Primary outcomes were adequate GWG and glycemic control in mothers and birth weight, birth leng

64 the rhythmic release of insulin and diurnal glycemic control in normal male and female mice.

65 ) induce substantial weight loss and improve glycemic control in patients with type 2 diabetes, but i

66 AG) is an emerging biomarker used to monitor glycemic control in persons with diabetes.

67 ification including weight loss and improved glycemic control in reducing arrhythmia recurrence follo

68 fer a novel therapeutic target for improving glycemic control in subjects with T2D.

69 subcutaneous adipocyte size predicted better glycemic control in T2D.

70 rum concentrations of Activin B and improved glycemic control in the db/db mouse model of T2D.

71 ce that increased foreclosure rates worsened glycemic control in this continuously insured population

72 Poor glycemic control is associated with cardiac autoimmunity

73 Recent evidence suggests that glycemic control is associated with cognitive function i

74 Poor glycemic control is associated with increased risk of ca

75 from several studies suggest that intensive glycemic control is associated with QT prolongation, whi

76 Of note, current glycemic control is not associated significantly with ei

77 Optimal glycemic control is particularly difficult to achieve in

78 The extended glycemic control led to distinctive improvements on redu

79 T1 contributes to the coordinated efforts in glycemic control may ultimately present novel therapeuti

80 ity after transplantation, but the effect of glycemic control on survival is unknown.We sought to det

81 ripheral, or hepatic IR or in any measure of glycemic control or beta-cell function.

82 were found between groups regarding maternal glycemic control or neonatal outcomes.

83 oglycemia and are associated with suboptimal glycemic control outcomes.

84 but statistically significant improvement in glycemic control over 26 weeks.

85 basal insulin), was efficacious in improving glycemic control over 52 weeks.

86 lationship between social adversity and poor glycemic control specially in urban areas of Bangladesh.

87 1c concentration were not available, and the glycemic control status was evaluated according to FPG v

88 d with standard care resulted in a change in glycemic control that did not reach the criterion for eq

89 Preconception glycemic control through appropriate methods is one of t

90 (1) R blockade in mice with obesity improves glycemic control through the hepatic Sirt1/mTORC2/Akt pa

91 TDM patients had satisfactory and comparable glycemic control throughout the follow-up period.

92 ndrial function in the regulation of optimal glycemic control to prevent T2D, but parkin's role in pr

93 in the association between low SES and poor glycemic control using data from the baseline survey of

94 IN5 on hepatic lipid metabolism and systemic glycemic control using liver-specific Plin5-deficient mi

95 in a daily insulin dose reduction and major glycemic control versus I-T1D.

96 Glycemic control was not associated with AAb prevalence

97 The improvement in glycemic control was observed without stimulation of the

98 Glycemic control was poorer in diabetic individuals with

99 of PECs to differentiate in vivo and restore glycemic control while confirming minimal proliferation

100 erapeutic potential owing to its long-acting glycemic control with improved cardiovascular function a

101 creasing systemic inflammation and providing glycemic control without increasing insulin, ABA extract

102 w risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 1

103 iciency Cohort for DKD phenotypes, including glycemic control, albuminuria, kidney function, and kidn

104 g, sleep apnea, blood pressure, and improved glycemic control, all of which may reduce AF burden.

105 anic and non-Hispanic black ethnicity, worse glycemic control, and elevated heart rate.

106 regain phase, might preserve weight loss and glycemic control, and is associated with specific microb

107 ucocorticoids (GCs) are essential for proper glycemic control, but in excess, can lead to hyperglycem

108 ave concluded that sleep contributes to poor glycemic control, diabetes management, and diabetes-rela

109 Compared with standard glycemic control, intensive glycemic control caused incr

110 significantly impaired insulin sensitivity, glycemic control, lipid metabolism, and sympathetic outp

111 Optimization of glycemic control, medication regimens, and careful atten

112 d T2DM, we examined analytes associated with glycemic control, metabolic processes, and T-cell-driven

113 ocioeconomic status (SES) is related to poor glycemic control, the underlying mechanisms remain uncle

114 1R expression is thought to be influenced by glycemic control, we examined the effect of blood glucos

115 f peripheral neuropathy is to maintain close glycemic control, while there is no recommendation for c

116 ure may lead to more durable weight loss and glycemic control.

117 ons to mitigate socioeconomic disparities in glycemic control.

118 ys a role for negative effects of statins on glycemic control.

119 re risk of developing DKD despite subsequent glycemic control.

120 two injections per day to maintain effective glycemic control.

121 es who may especially benefit from intensive glycemic control.

122 , which impaired systemic insulin action and glycemic control.

123 s an estimate of mean blood sugar levels and glycemic control.

124 ith diabetic animals rapidly re-establishing glycemic control.

125 in lower levels of TRLs - without improving glycemic control.

126 e diabetes-related biomarkers toward a tight glycemic control.

127 tric patients with T1D after one-year's poor glycemic control.

128 ears or longer at baseline, insulin use, and glycemic control.

129 n pharmacologic therapy is needed to improve glycemic control.

130 stinal glucose absorption in vivo to improve glycemic control.

131 ce of posttranscriptional gene regulation in glycemic control.

132 y of a fig fruit extract of ABA in promoting glycemic control.

133 associations of various sleep parameters and glycemic control.

134 residual C-peptide that likely contribute to glycemic control.FUNDINGFunding for this work was provid

135 er nut consumption is associated with better glycemic control; however, it is unclear if this associa

136 lanted, beta cell grafts can help to restore glycemic control; however, locating and retrieving cells

137 lting in long-term functional competence and glycemic correction (>150 days) without systemic immunos

138 Other ex vivo glycemic correlates occurred more generally in exposed F

139 ssigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucos

140 ent progression of beta-cell dysfunction and glycemic deterioration in models of T1D.

141 d sugar, sugar-sweetened beverages, and high-glycemic diets were associated with greater weight gain

142 pathogenesis, and when normalized with anti-glycemic drugs would improve clinical outcomes.

143 isplay both distinct and shared longitudinal glycemic dysregulation patterns, temporal co-occurrences

144 has uncovered dozens of loci that influence glycemic dysregulation.

145 Because Neu5Gc(-/-) mice exhibit glycemic dysregulations and pancreatic beta-cell dysfunc

146 tential mechanisms explaining the cumulative glycemic effect are also briefly discussed.

147 h most research has been directed toward the glycemic effects of weight loss surgery, there has been

148 A limitation to this study involves glycemic effects on brain function; because blood glucos

149 iogenesis, running endurance, and beneficial glycemic effects were lost in Il13(-/-) mice.

150 Given its glycemic efficacy and ability to reduce the body weight,

151 h type 2 diabetes mellitus, while aiming for glycemic equipoise.

152 glucose-lowering agents under the premise of glycemic equipoise.

153 ther meal rankings according to postprandial glycemic excursions differ between 2 simultaneously worn

154 sonalize meal recommendations for minimizing glycemic excursions may be premature given the discordan

155 and glycemic variability (mean amplitude of glycemic excursions) were reduced with the LCBF (24-h in

156 dant meal rankings according to postprandial glycemic excursions.

157 +/- 361 mmol/L; P = 0.03; mean amplitude of glycemic excursions: -0.4 +/- 0.8 mmol/L . 24 h; P = 0.0

158 can be largely explained by lower cumulative glycemic exposure in the intensive therapy group, and, o

159 ment of complications increases with greater glycemic exposure, irrespective of whether this results

160 le with type 1 diabetes do not achieve their glycemic goals(1).

161 associated with a significant modulation of glycemic, hormonal, and cytokine parameters in T2DM and

162 e of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered

163 ere performed to classify subjects with good glycemic improvements.

164 60% carbohydrate, 20% fat, 20% protein), low glycemic index (40% carbohydrate, 40% fat, 20% protein),

165 ysis (0.0140 vs 0.0050) with lower estimated glycemic index (61.29 vs 65.84) than Xanthosoma spp. gel

166 h fractions (3.87-10.96%) with low predicted glycemic index (62.97-53.13%), despite their higher tota

167 A high glycemic index (beta: 0.25; 95% CI: 0.07, 0.42; P = 0.00

168 tive of this study was to lower the expected glycemic index (eGI) of two white rice cultivars, 'KDML1

169 s of both products thereby reducing expected glycemic index (eGI) while the in vitro protein digestib

170 iological studies indicate that high dietary glycemic index (GI) and glycemic load (GL) are associate

171 vious findings on the association of dietary glycemic index (GI) and glycemic load (GL) with mortalit

172 the association between midpregnancy dietary glycemic index (GI), glycemic load (GL), and sugar-sweet

173 dies are needed that measure overall dietary glycemic index (GI), glycemic load, and intakes of speci

174 study was to evaluate the nutritional value, glycemic index (GI), total phenol content (TPC), and tot

175 digestible starch (DS) content and estimated glycemic index (pGI) (25.0% and 59.3, respectively).

176 Physicochemical properties, predicted glycemic index (pGI) and bread qualities of a non-pigmen

177 It also markedly lowered the bread predicted glycemic index and improved in vitro protein digestibili

178 obtained, resulting in medium to low (55-69) glycemic index breads.

179 loss maintenance diets based on protein and glycemic index content and followed up for 26 wk.

180 Low-glycemic index diets have demonstrated health benefits a

181 could lower the glycemic response of a high-glycemic index food when consumed together and the mecha

182 added sugar consumption, glycemic load, and glycemic index have been linked with weight gain, wherea

183 major source of carbohydrates, but its high glycemic index makes it unsuitable for diabetics.

184 DRRD score was derived with 9 factors: lower glycemic index of diet; lower intakes of trans fat, suga

185 he digestion of starch, thus, decreasing the glycemic index of pasta.

186 operties, starch digestibility and estimated glycemic index of wheat bread were studied.

187 ents in the product formulations lowered the glycemic index probably by inhibiting carbohydrate hydro

188 The estimated glycemic index reflected the changes promoted on starch

189 Millets predicted lower glycemic index than wheat and it was found to be negativ

190 getarian, Paleolithic, low-carbohydrate, low glycemic index, high-protein, and low-fat diets was inco

191 low-carbohydrate, low-fat, high-protein, low glycemic index, portfolio, pulse, and Paleolithic diets

192 pasting properties, starch digestibility and glycemic index, revealing that the effects observed are

193 d on 4 criteria (total dietary fiber intake, glycemic index, whole grain/total grain ratio, and solid

194 ible starch, resistant starch, and predicted glycemic index.

195 om seven tef varieties and to estimate their glycemic index.

196 s of added sugar, sugary beverages, and high-glycemic-index and -load diets were partially attenuated

197 ly modified and had modestly lower estimated glycemic indexes and significantly lower gelatinization

198 ciations between plasma PFAS concentrations, glycemic indicators, and diabetes incidence among high-r

199 Such patients had higher glycemic lability, hemoglobin A1C levels, and Acute Phys

200 next generation diagnostic tool for personal glycemic level management.

201 physical activity, and metabolic (including glycemic), lipid and anthropometric traits, independent

202 ects of 11 metabolic risk factors, including glycemic, lipid, and adiposity traits, on ACR.

203 ta: 0.25; 95% CI: 0.07, 0.42; P = 0.006) and glycemic load (beta: 0.04; 95% CI: 0.002, 0.08; P = 0.04

204 te that high dietary glycemic index (GI) and glycemic load (GL) are associated with increased CHD ris

205 was the only one eliciting low GI of 50 and glycemic load (GL) of 13 while the rest exhibited GI ran

206 Glycemic load (GL) reflects the quantity and quality of

207 sociation of dietary glycemic index (GI) and glycemic load (GL) with mortality are conflicting.

208 en midpregnancy dietary glycemic index (GI), glycemic load (GL), and sugar-sweetened beverages and th

209 rate, fat, saturated fat, dietary fiber, and glycemic load derived from self-report of dietary intake

210 results support beneficial effects of a low-glycemic load dietary pattern characterized by whole gra

211 Low-glycemic load dietary patterns, characterized by consump

212 We hypothesized that higher GI and glycemic load would be associated with greater odds of i

213 e quality including added sugar consumption, glycemic load, and glycemic index have been linked with

214 measure overall dietary glycemic index (GI), glycemic load, and intakes of specific types of carbohyd

215 al Study, investigating the relations of GI, glycemic load, other carbohydrate measures (added sugars

216 WMD) intervention with arms having different glycemic loads.

217 In this document, we discuss the role of glycemic management (both in intensity of control and ch

218 Estimates of cross-sectional associations of glycemic markers (fasting plasma glucose, HbA(1C), and h

219 ckground We investigated the associations of glycemic markers (HbA(1C) [hemoglobin A(1C)], fasting pl

220 Conclusions Among blacks, glycemic markers were differentially associated with var

221 e effects on the mean change in postprandial glycemic or insulinemic responses compared with a contro

222 ods were used to assess risk of bias for the glycemic outcome and to prepare a summary of findings ta

223 We conducted a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c).

224 Further research is needed to assess non-glycemic outcomes and to study implementation in rural a

225 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD.

226 o called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.

227 the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-pha

228 s that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes.

229 Non-glycemic outcomes of mortality, health-related quality o

230 tudies, and sparse data availability for non-glycemic outcomes.

231 es in obese T2D patients and correlates with glycemic parameters and with the number of ILC1s in the

232 The chemical composition and in vivo glycemic potential of popular Indian rice varieties name

233 te C-peptide response to arginine at maximal glycemic potentiation did not significantly correlate wi

234 312 [0.057] per SD; P = 5.84 x 10-8) but not glycemic progression (HR: 1.01 [95% CI 0.96-1.05] per SD

235 of diabetes, yet the factors that influence glycemic progression are not well understood.

236 and other clinical and genetic factors with glycemic progression defined as requirement of continuou

237 tify the clinical and genetic predictors for glycemic progression in Chinese patients with T2D.

238 d of 8.8 (IQR: 4.8-13.3) years, incidence of glycemic progression was 48.0 (95% confidence interval [

239 e were additional independent predictors for glycemic progression.

240 control of multiple risk factors to prevent glycemic progression.

241 t predicted both triglyceride (r = 0.47) and glycemic (r = 0.77) responses to food intake.

242 greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insuli

243 ott resulted in 50 +/- 10% (P = 0.0002) less glycemic reduction as measured by Dexcom, and vice versa

244 The missing glycemic reduction by eating meals ranked according to t

245 to be unique genetic influences on pregnancy glycemic regulation that contribute to GDM.

246 ther pomegranate polyphenols could lower the glycemic response of a high-glycemic index food when con

247 y used to guide interventions to control the glycemic response to food have low efficacy, with recent

248 redictive model of personalized postprandial glycemic response to foods that was developed with an Is

249 continuous glucose monitors for 6 d, and the glycemic response to meals logged during this time was c

250 o personalize diets to minimize postprandial glycemic responses as measured by continuous glucose mon

251 Starch is a major determinant of the glycemic responses elicited by our diets, but the exact

252 d by the Israeli cohort to correctly predict glycemic responses in the Midwestern cohort was assessed

253 ed with those in the top half of incremental glycemic responses ranked by Abbott resulted in 50 +/- 1

254 fective nutritional interventions to control glycemic responses to foods.

255 Within-subject meal rankings for incremental glycemic responses were relatively discordant between CG

256 termines its effect on serum cholesterol and glycemic responses, but whether OBG viscosity affects ga

257 tality in critically ill patients across the glycemic spectrum.

258 , stratified by age (<65 and >=65 years) and glycemic status (diabetes or prediabetes).

259 were compared between groups with respect to glycemic status and body mass index (BMI).

260 pants were divided into four groups based on glycemic status and self-reported cigarette-smoking habi

261 onclusion, gamma-GT concentration as well as glycemic status could be a future risk factor for dement

262 We aimed to examine the effect of glycemic status evaluated by hemoglobin A1c (HbA1c) on t

263 ditional information is needed about whether glycemic status influences the magnitude of their benefi

264 with atrial fibrillation, and differences in glycemic status may affect this risk.

265 trointestinal symptoms, waist circumference, glycemic status, and changes in the gut microbiome, as m

266 ma-GT on dementia was observed regardless of glycemic status, and prevalent diabetes with the highest

267 iation of early-life nutrition and long-term glycemic status.

268 ased glucose test to determine the patient's glycemic status.

269 ased HbA(1c) test to determine the patient's glycemic status.

270 t via fingerstick to determine the patient's glycemic status.

271 treatment failure, or death did not vary by glycemic status.

272 ent of HFrEF patients independently of their glycemic status.

273 with type 1 diabetes do not meet recommended glycemic targets.

274 Do not perform glycemic testing because it is not indicated for this pa

275 Glycemic therapy was deintensified in 18.3% of patients

276 enuates adipose tissue fibrosis and improves glycemic tolerance.

277 fat mass, fat-free mass, physical activity, glycemic traits and 17 psychiatric traits (up to N = 217

278 standing of how genetic loci associated with glycemic traits and type 2 diabetes (T2D) influence the

279 n tested for associations between scores and glycemic traits as well as pharmacodynamic end points, a

280 osition to type 2 diabetes (T2D) and related glycemic traits, and human pancreatic islet transcriptio

281 et cis-eQTLs and variants influencing T2D or glycemic traits, including DGKB and TCF7L2.

282 th anthropometric, hematological, lipid, and glycemic traits.

283 summary data for multiple lipids traits and glycemic traits.

284 ve hyperglycemia to determine individualized glycemic treatment targets improves outcomes in ICU.

285 Investigators were encouraged to intensify glycemic treatment, primarily by adding or adjusting met

286 ncremental area under the glucose curve) and glycemic variability (mean amplitude of glycemic excursi

287 8 mo; P = 0.006), and more patients with low glycemic variability and C-peptide >=1.0 ng/mL, at month

288 ity insulin therapy was designed to mitigate glycemic variability and hypoglycemia through avoidance

289 Dysglycemia and glycemic variability are associated with poor outcomes i

290 mbers with plasma C-peptide >=0.5 ng/mL, low glycemic variability associated with C-peptide >=1.0 ng/

291 Glycemic variability decreased by 28.6% (p < 0.0001).

292 to measure hypoglycemia, hyperglycemia, and glycemic variability for 5 days followed by (1)H MRS sca

293 These findings that glycemic variability is associated with brain glucose le

294 ical evidence suggests both hypoglycemia and glycemic variability negatively impact patient outcomes.

295 future studies to investigate the impact of glycemic variability on brain glucose kinetics.

296 The impact of glycemic variability on brain glucose transport kinetics

297 re to postprandial hyperglycemia and improve glycemic variability.

298 ich appeared to be associated with decreased glycemic variability.

299 AMY1 CN was not associated with baseline glycemic variables.

300 d the effects on metabolic profiles of a low-glycemic whole-grain dietary pattern (WG) compared with